hyperphenylalaninemia

Broad label FDA approval for phenylketonuria drug

31 July 2025 | By Catherine Eckford (European Pharmaceutical Review)

Alongside Phase III data demonstrating significant efficacy in the rare disease, the FDA’s decision could position the small molecule as a future standard of care.